The regulation of miRNAs in inflammation-related carcinogenesis

Current Pharmaceutical Design

Volumn 21, Issue 21, 2015, Pages 3023-3031

  Ma, Yiming ^a   Han, Wenxiao ^a   Yang, Lan ^a   He, Longmei ^a   Wang, Hongying ^a  

^a CANCER HOSPITAL   (China)

Author keywords

Biosynthesis; Carcinogenesis; Inflammation; MiRNAs

Indexed keywords

IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; MICRORNA; MICRORNA 155; MICRORNA 181; MICRORNA 21; PROTEIN P53; STAT PROTEIN; UNCLASSIFIED DRUG;

ARTICLE; BIOSYNTHESIS; CANCER GENETICS; CARCINOGENESIS; CHRONIC INFLAMMATION; CYTOPLASM; EPIGENETICS; FEEDBACK SYSTEM; GENE EXPRESSION; GENE LOCUS; GENE MUTATION; HUMAN; INFLAMMATION RELATED CARCINOGENESIS; MALIGNANT NEOPLASTIC DISEASE; NONHUMAN; ONCOGENE; PRIORITY JOURNAL; PROTEIN EXPRESSION; REGULATORY MECHANISM; RNA METHYLATION; RNA STABILITY; TRANSCRIPTION REGULATION; ANIMAL; CHRONIC DISEASE; COMPLICATION; GENETICS; INFLAMMATION; NEOPLASMS; SIGNAL TRANSDUCTION;

ANIMALS; CARCINOGENESIS; CHRONIC DISEASE; HUMANS; INFLAMMATION; MICRORNAS; NEOPLASMS; SIGNAL TRANSDUCTION;

EID: 84931857818     PISSN: 13816128     EISSN: 18734286     Source Type: Journal    
DOI: 10.2174/1381612821666150514105606     Document Type: Article

References (129)

1. Coussens LM, Werb Z. Inflammation and cancer. Nature 2002; 420(6917): 860-7.
2. Mantovani A, Allavena P, Sica A, Balkwill F. Cancer-related inflammation. Nature 2008; 454(7203): 436-44.
3. Parkin DM. The global health burden of infection-associated cancers in the year 2002. Int J Cancer 2006; 118(12): 3030-44.
4. Coussens LM, Werb Z. Inflammation and cancer. Nature 2002; 420(6917): 860-7.
5. Velayos FS, Loftus EV Jr, Jess T, et al. Predictive and protective factors associated with colorectal cancer in ulcerative colitis: A case-control study. Gastroenterology 2006; 130(7): 1941-9.
6. Dranoff G. Cytokines in cancer pathogenesis and cancer therapy. Nat Rev Cancer 2004; 4(1): 11-22.
7. Lippitz BE. Cytokine patterns in patients with cancer: a systematic review. Lancet Oncol 2013; 14(6): e218-28.
8. Barnes PJ, Karin M. Nuclear factor-kappaB: a pivotal transcription factor in chronic inflammatory diseases. N Engl J Med 1997; 336(15): 1066-71.
9. Ben-Neriah Y, Karin M. Inflammation meets cancer, with NFkappaB as the matchmaker. Nat Immunol 2011; 12(8): 715-23.
10. Greten FR, Eckmann L, Greten TF, et al. IKKbeta links inflammation and tumorigenesis in a mouse model of colitisassociated cancer. Cell 2004; 118(3): 285-96.
11. Pikarsky E, Porat RM, Stein I, et al. NF-kappaB functions as a tumour promoter in inflammation-associated cancer. Nature 2004; 431(7007): 461-6.
12. Zhou J, Schmid T, Brune B. HIF-1alpha and p53 as targets of NO in affecting cell proliferation, death and adaptation. Curr Mol Med 2004; 4(7): 741-51.
13. Rivlin N, Brosh R, Oren M, Rotter V. Mutations in the p53 tumor suppressor gene: important milestones at the various steps of tumorigenesis. Genes Cancer 2011; 2(4): 466-74.
14. Ullman TA, Itzkowitz SH. Intestinal inflammation and cancer. Gastroenterology 2011; 140(6): 1807-16.
15. Cooks T, Pateras IS, Tarcic O, et al. Mutant p53 prolongs NFkappaB activation and promotes chronic inflammation and inflammation-associated colorectal cancer. Cancer Cell 2013; 23(5): 634-46.
16. Okazaki IM, Kotani A, Honjo T. Role of AID in tumorigenesis. Adv Immunol 2007; 94: 245-73.
17. Soreide K, Janssen EA, Soiland H, Korner H, Baak JP. Microsatellite instability in colorectal cancer. Br J Surg 2006; 93(4): 395-406.
18. Hsieh CJ, Klump B, Holzmann K, Borchard F, Gregor M, Porschen R. Hypermethylation of the p16INK4a promoter in colectomy specimens of patients with long-standing and extensive ulcerative colitis. Cancer Res 1998; 58(17): 3942-5.
19. Matsusaka K, Funata S, Fukayama M, Kaneda A. DNA methylation in gastric cancer, related to helicobacter pylori and epstein-barr virus. World J Gastroenterol 2014; 20(14): 3916-26.
20. Hmadcha A, Bedoya FJ, Sobrino F, Pintado E. Methylationdependent gene silencing induced by interleukin 1beta via nitric oxide production. J Exp Med 1999; 190(11): 1595-604.
21. Hodge DR, Xiao W, Clausen PA, Heidecker G, Szyf M, Farrar WL. Interleukin-6 regulation of the human DNA methyltransferase (HDNMT) gene in human erythroleukemia cells. J Biol Chem 2001; 276(43): 39508-11.
22. Braconi C, Huang N, Patel T. MicroRNA-dependent regulation of DNA methyltransferase-1 and tumor suppressor gene expression by interleukin-6 in human malignant cholangiocytes. Hepatology 2010; 51(3): 881-90.
23. Lee RC, Feinbaum RL, Ambros V. The C. elegans heterochronic gene lin-4 encodes small RNAs with antisense complementarity to lin-14. Cell 1993; 75(5): 843-54.
24. Lewis BP, Burge CB, Bartel DP. Conserved seed pairing, often flanked by adenosines, indicates that thousands of human genes are microRNA targets. Cell 2005; 120(1): 15-20.
25. Friedman RC, Farh KK, Burge CB, Bartel DP. Most mammalian mRNAs are conserved targets of microRNAs. Genome Res 2009; 19(1): 92-105.
26. Kawamata T, Tomari Y. Making RISC. Trends Biochem Sci 2010; 35(7): 368-76.
27. Kawamata T, Seitz H, Tomari Y. Structural determinants of miRNAs for RISC loading and slicer-independent unwinding. Nat Struct Mol Biol 2009; 16(9): 953-60.
28. Bartel DP. MicroRNAs: target recognition and regulatory functions. Cell 2009; 136(2): 215-33.
29. Xie B, Ding Q, Han H, Wu D. miRCancer: a microRNA-cancer association database constructed by text mining on literature. Bioinformatics 2013; 29(5): 638-44.
30. Aleckovic M, Kang Y. Regulation of cancer metastasis by cell-free miRNAs. Biochim Biophys Acta 2015; 1855(1): 24-42.
31. Khraiwesh B, Arif MA, Seumel GI, et al. Transcriptional control of gene expression by microRNAs. Cell 2010; 140(1): 111-22.
32. Shukla GC, Singh J, Barik S. MicroRNAs: processing, maturation, target recognition and regulatory functions. Mol Cell Pharmacol 2011; 3(3): 83-92.
33. McKenna LB, Schug J, Vourekas A, et al. MicroRNAs control intestinal epithelial differentiation, architecture, and barrier function. Gastroenterology 2010; 139(5): 1654-64, 1664.
34. Hu M, Xia M, Chen X, et al. MicroRNA-141 regulates Smad interacting protein 1 (SIP1) and inhibits migration and invasion of colorectal cancer cells. Dig Dis Sci 2010; 55(8): 2365-72.
35. Jia HY, Wang YX, Yan WT, et al. MicroRNA-125b functions as a tumor suppressor in hepatocellular carcinoma cells. Int J Mol Sci 2012; 13(7): 8762-74.
36. Zhou W, Fong MY, Min Y, et al. Cancer-secreted miR-105 destroys vascular endothelial barriers to promote metastasis. Cancer Cell 2014; 25(4): 501-15.
37. Yang R, Dick M, Marme F, et al. Genetic variants within miR-126 and miR-335 are not associated with breast cancer risk. Breast Cancer Res Treat 2011; 127(2): 549-54.
38. Wu D, Ding J, Wang L, et al. microRNA-125b inhibits cell migration and invasion by targeting matrix metallopeptidase 13 in bladder cancer. Oncol Lett 2013; 5(3): 829-34.
39. Chapman CG, Pekow J. The emerging role of miRNAs in inflammatory bowel disease: a review. Therap Adv Gastroenterol 2015; 8(1): 4-22.
40. Runtsch MC, Round JL, O'Connell RM. MicroRNAs and the regulation of intestinal homeostasis. Front Genet 2014; 5: 347.
41. Ha M, Kim VN. Regulation of microRNA biogenesis. Nat Rev Mol Cell Biol 2014; 15(8): 509-24.
42. Cai X, Hagedorn CH, Cullen BR. Human microRNAs are processed from capped, polyadenylated transcripts that can also function as mRNAs. RNA 2004; 10(12): 1957-66.
43. Zeng Y, Cullen BR. Structural requirements for pre-microRNA binding and nuclear export by Exportin 5. Nucleic Acids Res 2004; 32(16): 4776-85.
44. Hutvagner G, McLachlan J, Pasquinelli AE, Balint E, Tuschl T, Zamore PD. A cellular function for the RNA-interference enzyme Dicer in the maturation of the let-7 small temporal RNA. Science 2001; 293(5531): 834-8.
45. Chendrimada TP, Gregory RI, Kumaraswamy E, et al. TRBP recruits the Dicer complex to Ago2 for microRNA processing and gene silencing. Nature 2005; 436(7051): 740-4.
46. Schwarz DS, Hutvagner G, Du T, Xu Z, Aronin N, Zamore PD. Asymmetry in the assembly of the RNAi enzyme complex. Cell 2003; 115(2): 199-208.
47. Khvorova A, Reynolds A, Jayasena SD. Functional siRNAs and miRNAs exhibit strand bias. Cell 2003; 115(2): 209-16.
48. Romero-Cordoba S, Rodriguez-Cuevas S, Rebollar-Vega R, et al. Identification and pathway analysis of microRNAs with no previous involvement in breast cancer. PLoS One 2012; 7(3): e31904.
49. Marco A, Macpherson JI, Ronshaugen M, Griffiths-Jones S. MicroRNAs from the same precursor have different targeting properties. Silence 2012; 3(1): 8.
50. Madhyastha R, Madhyastha H, Pengjam Y, Nakajima Y, Omura S, Maruyama M. NFkappaB activation is essential for miR-21 induction by TGFbeta1 in high glucose conditions. Biochem Biophys Res Commun 2014; 451(4): 615-21.
51. Lee KS, Kim J, Kwak SN, et al. Functional role of NF-kappaB in expression of human endothelial nitric oxide synthase. Biochem Biophys Res Commun 2014; 448(1): 101-7.
52. Zhang X, Liu S, Hu T, Liu S, He Y, Sun S. Up-regulated microRNA-143 transcribed by nuclear factor kappa B enhances hepatocarcinoma metastasis by repressing fibronectin expression. Hepatology 2009; 50(2): 490-9.
53. Taganov KD, Boldin MP, Chang KJ, Baltimore D. NF-kappaBdependent induction of microRNA miR-146, an inhibitor targeted to signaling proteins of innate immune responses. Proc Natl Acad Sci USA 2006; 103(33): 12481-6.
54. Taganov KD, Boldin MP, Chang KJ, Baltimore D. NF-kappaBdependent induction of microRNA miR-146, an inhibitor targeted to signaling proteins of innate immune responses. Proc Natl Acad Sci USA 2006; 103(33): 12481-6.
55. Bhaumik D, Patil CK, Campisi J. MicroRNAs: an important player in maintaining a balance between inflammation and tumor suppression. Cell Cycle 2009; 8(12): 1822.
56. Perry MM, Moschos SA, Williams AE, Shepherd NJ, Larner- Svensson HM, Lindsay MA. Rapid changes in microRNA-146a expression negatively regulate the IL-1beta-induced inflammatory response in human lung alveolar epithelial cells. J Immunol 2008; 180(8): 5689-98.
57. Li Y, VandenBoom TG, Wang Z, et al. Up-regulation of miR-146a contributes to the inhibition of invasion of pancreatic cancer cells. Cancer Res 2010; 70(8 Suppl): 5703.
58. Lin SL, Chiang A, Chang D, Ying SY. Loss of mir-146a function in hormone-refractory prostate cancer. RNA 2008; 14(3): 417-24.
59. Bhaumik D, Scott GK, Schokrpur S, Patil CK, Campisi J, Benz CC. Expression of microRNA-146 suppresses NF-kappaB activity with reduction of metastatic potential in breast cancer cells. Oncogene 2008; 27(42): 5643-7.
60. Forrester K, Ambs S, Lupold SE, et al. Nitric oxide-induced p53 accumulation and regulation of inducible nitric oxide synthase expression by wild-type p53. Proc Natl Acad Sci USA 1996; 93(6): 2442-7.
61. Schetter AJ, Heegaard NH, Harris CC. Inflammation and cancer: interweaving microRNA, free radical, cytokine and p53 pathways. Carcinogenesis 2010; 31(1): 37-49.
62. Itzkowitz SH, Greenwald B, Meltzer SJ. Colon carcinogenesis in inflammatory bowel disease. Inflamm Bowel Dis 1995; 1(2): 142- 58.
63. Raver-Shapira N, Marciano E, Meiri E, et al. Transcriptional activation of miR-34a contributes to p53-mediated apoptosis. Mol Cell 2007; 26(5): 731-43.
64. Kim T, Veronese A, Pichiorri F, et al. p53 regulates epithelialmesenchymal transition through microRNAs targeting ZEB1 and ZEB2. J Exp Med 2011; 208(5): 875-83.
65. Fabbri M, Bottoni A, Shimizu M, et al. Association of a microRNA/TP53 feedback circuitry with pathogenesis and outcome of B-cell chronic lymphocytic leukemia. JAMA 2011; 305(1): 59- 67.
66. Braun CJ, Zhang X, Savelyeva I, et al. p53-Responsive micrornas 192 and 215 are capable of inducing cell cycle arrest. Cancer Res 2008; 68(24): 10094-104.
67. Bohlig L, Friedrich M, Engeland K. p53 activates the PANK1/miRNA-107 gene leading to downregulation of CDK6 and p130 cell cycle proteins. Nucleic Acids Res 2011; 39(2): 440-53.
68. Sachdeva M, Zhu S, Wu F, et al. p53 represses c-Myc through induction of the tumor suppressor miR-145. Proc Natl Acad Sci USA 2009; 106(9): 3207-12.
69. Sachdeva M, Zhu S, Wu F, et al. p53 represses c-Myc through induction of the tumor suppressor miR-145. Proc Natl Acad Sci USA 2009; 106(9): 3207-12.
70. Michael MZ, O' Connor SM, van Holst Pellekaan NG, Young GP, James RJ. Reduced accumulation of specific microRNAs in colorectal neoplasia. Mol Cancer Res 2003; 1(12): 882-91.
71. Pekow JR, Dougherty U, Mustafi R, et al. miR-143 and miR-145 are downregulated in ulcerative colitis: putative regulators of inflammation and protooncogenes. Inflamm Bowel Dis 2012; 18(1): 94-100.
72. Kent OA, Fox-Talbot K, Halushka MK. RREB1 repressed miR- 143/145 modulates KRAS signaling through downregulation of multiple targets. Oncogene 2013; 32(20): 2576-85.
73. Noguchi S, Yasui Y, Iwasaki J, et al. Replacement treatment with microRNA-143 and -145 induces synergistic inhibition of the growth of human bladder cancer cells by regulating PI3K/Akt and MAPK signaling pathways. Cancer Lett 2013; 328(2): 353-61.
74. Rozovski U, Calin GA, Setoyama T, et al. Signal transducer and activator of transcription (STAT)-3 regulates microRNA gene expression in chronic lymphocytic leukemia cells. Mol Cancer 2013; 12: 50.
75. Kutty RK, Nagineni CN, Samuel W, Vijayasarathy C, Hooks JJ, Redmond TM. Inflammatory cytokines regulate microRNA-155 expression in human retinal pigment epithelial cells by activating JAK/STAT pathway. Biochem Biophys Res Commun 2010; 402(2): 390-5.
76. Iliopoulos D, Jaeger SA, Hirsch HA, Bulyk ML, Struhl K. STAT3 activation of miR-21 and miR-181b-1 via PTEN and CYLD are part of the epigenetic switch linking inflammation to cancer. Mol Cell 2010; 39(4): 493-506.
77. Brock M, Trenkmann M, Gay RE, et al. Interleukin-6 modulates the expression of the bone morphogenic protein receptor type II through a novel STAT3-microRNA cluster 17/92 pathway. Circ Res 2009; 104(10): 1184-91.
78. Li H, Xie S, Liu M, et al. The clinical significance of downregulation of mir-124-3p, mir-146a-5p, mir-155-5p and mir- 335-5p in gastric cancer tumorigenesis. Int J Oncol 2014; 45(1): 197-208.
79. Ueda Y, Ando T, Nanjo S, Ushijima T, Sugiyama T. DNA methylation of microRNA-124a is a potential risk marker of colitisassociated cancer in patients with ulcerative colitis. Dig Dis Sci 2014; 59(10): 2444-51.
80. Chang S, Wang RH, Akagi K, et al. Tumor suppressor BRCA1 epigenetically controls oncogenic microRNA-155. Nat Med 2011; 17(10): 1275-82.
81. Suzuki HI, Yamagata K, Sugimoto K, Iwamoto T, Kato S, Miyazono K. Modulation of microRNA processing by p53. Nature 2009; 460(7254): 529-33.
82. Chen X, Guo X, Zhang H, et al. Role of miR-143 targeting KRAS in colorectal tumorigenesis. Oncogene 2009; 28(10): 1385-92.
83. Pekow JR, Dougherty U, Mustafi R, et al. miR-143 and miR-145 are downregulated in ulcerative colitis: putative regulators of inflammation and protooncogenes. Inflamm Bowel Dis 2012; 18(1): 94-100.
84. Kanaan Z, Rai SN, Eichenberger MR, et al. Differential microRNA expression tracks neoplastic progression in inflammatory bowel disease-associated colorectal cancer. Hum Mutat 2012; 33(3): 551- 60.
85. Wu XL, Cheng B, Li PY, et al. MicroRNA-143 suppresses gastric cancer cell growth and induces apoptosis by targeting COX-2. World J Gastroenterol 2013; 19(43): 7758-65.
86. Davis BN, Hilyard AC, Nguyen PH, Lagna G, Hata A. Smad proteins bind a conserved RNA sequence to promote microRNA maturation by Drosha. Mol Cell 2010; 39(3): 373-84.
87. Adorno M, Cordenonsi M, Montagner M, et al. A Mutantp53/ Smad complex opposes p63 to empower TGFbeta-induced metastasis. Cell 2009; 137(1): 87-98.
88. Paroo Z, Ye X, Chen S, Liu Q. Phosphorylation of the human microRNA-generating complex mediates MAPK/Erk signaling. Cell 2009; 139(1): 112-22.
89. Jiang X. Different signal pathways regulate IL-1beta-induced mature and primary miRNA-146a expression in human alveolar epithelial cells. Acta Physiol Hung 2014; 101(3): 282-90.
90. Herman JG, Umar A, Polyak K, et al. Incidence and functional consequences of hMLH1 promoter hypermethylation in colorectal carcinoma. Proc Natl Acad Sci USA 1998; 95(12): 6870-5.
91. Fleisher AS, Esteller M, Wang S, et al. Hypermethylation of the hMLH1 gene promoter in human gastric cancers with microsatellite instability. Cancer Res 1999; 59(5): 1090-5.
92. Coskun M, Bjerrum JT, Seidelin JB, Troelsen JT, Olsen J, Nielsen OH. miR-20b, miR-98, miR-125b-1*, and let-7e* as new potential diagnostic biomarkers in ulcerative colitis. World J Gastroenterol 2013; 19(27): 4289-99.
93. Newman MA, Thomson JM, Hammond SM. Lin-28 interaction with the Let-7 precursor loop mediates regulated microRNA processing. RNA 2008; 14(8): 1539-49.
94. Iliopoulos D, Hirsch HA, Struhl K. An epigenetic switch involving NF-kappaB, Lin28, Let-7 MicroRNA, and IL6 links inflammation to cell transformation. Cell 2009; 139(4): 693-706.
95. Sokhi UK, Bacolod MD, Dasgupta S, et al. Identification of genes potentially regulated by human polynucleotide phosphorylase (hPNPase old-35) using melanoma as a model. PLoS One 2013; 8(10): e76284.
96. Bai J, Li Y, Shao T, et al. Integrating analysis reveals microRNAmediated pathway crosstalk among Crohn's disease, ulcerative colitis and colorectal cancer. Mol Biosyst 2014; 10(9): 2317-28.
97. Hu G, Gong AY, Liu J, Zhou R, Deng C, Chen XM. miR-221 suppresses ICAM-1 translation and regulates interferon-gammainduced ICAM-1 expression in human cholangiocytes. Am J Physiol Gastrointest Liver Physiol 2010; 298(4): G542-50.
98. Ma L, Zhu L, Gu D, et al. A genetic variant in miR-146a modifies colorectal cancer susceptibility in a Chinese population. Arch Toxicol 2013; 87(5): 825-33.
99. Heo I, Joo C, Kim YK, et al. TUT4 in concert with Lin28 suppresses microRNA biogenesis through pre-microRNA uridylation. Cell 2009; 138(4): 696-708.
100. Ji L, Chen X. Regulation of small RNA stability: methylation and beyond. Cell Res 2012; 22(4): 624-36.
101. Yuan S, Tang H, Xing J, et al. Methylation by NSun2 represses the levels and function of microRNA 125b. Mol Cell Biol 2014; 34(19): 3630-41.
102. Frye M, Watt FM. The RNA methyltransferase Misu (NSun2) mediates Myc-induced proliferation and is upregulated in tumors. Curr Biol 2006; 16(10): 971-81.
103. Okamoto M, Hirata S, Sato S, et al. Frequent increased gene copy number and high protein expression of tRNA (cytosine-5-)- methyltransferase (NSUN2) in human cancers. DNA Cell Biol 2012; 31(5): 660-71.
104. Blanco S, Kurowski A, Nichols J, Watt FM, Benitah SA, Frye M. The RNA-methyltransferase Misu (NSun2) poises epidermal stem cells to differentiate. PLoS Genet 2011; 7(12): e1002403.
105. Frye M, Watt FM. The RNA methyltransferase Misu (NSun2) mediates Myc-induced proliferation and is upregulated in tumors. Curr Biol 2006; 16(10): 971-81.
106. Faltejskova P, Besse A, Sevcikova S, et al. Clinical correlations of miR-21 expression in colorectal cancer patients and effects of its inhibition on DLD1 colon cancer cells. Int J Colorectal Dis 2012; 27(11): 1401-8.
107. Sheedy FJ, Palsson-McDermott E, Hennessy EJ, et al. Negative regulation of TLR4 via targeting of the proinflammatory tumor suppressor PDCD4 by the microRNA miR-21. Nat Immunol 2010; 11(2): 141-7.
108. Madhyastha R, Madhyastha H, Pengjam Y, Nakajima Y, Omura S, Maruyama M. NFkappaB activation is essential for miR-21 induction by TGFbeta1 in high glucose conditions. Biochem Biophys Res Commun 2014; 451(4): 615-21.
109. Koole W, Schafer HS, Agami R, van HG, Tijsterman M. A versatile microsatellite instability reporter system in human cells. Nucleic Acids Res 2013; 41(16): e158.
110. Deng J, Lei W, Fu JC, Zhang L, Li JH, Xiong JP. Targeting miR-21 enhances the sensitivity of human colon cancer HT-29 cells to chemoradiotherapy in vitro. Biochem Biophys Res Commun 2014; 443(3): 789-95.
111. Chao TF, Xiong HH, Liu W, Chen Y, Zhang JX. MiR-21 mediates the radiation resistance of glioblastoma cells by regulating PDCD4 and hMSH2. J Huazhong Univ Sci Technol Med Sci 2013; 33(4): 525-9.
112. Valeri N, Gasparini P, Braconi C, et al. MicroRNA-21 induces resistance to 5-fluorouracil by down-regulating human DNA MutS homolog 2 (hMSH2). Proc Natl Acad Sci USA 2010; 107(49): 21098-103.
113. Iliopoulos D, Jaeger SA, Hirsch HA, Bulyk ML, Struhl K. STAT3 activation of miR-21 and miR-181b-1 via PTEN and CYLD are part of the epigenetic switch linking inflammation to cancer. Mol Cell 2010; 39(4): 493-506.
114. Svrcek M, El-Murr N, Wanherdrick K, et al. Overexpression of microRNAs-155 and 21 targeting mismatch repair proteins in inflammatory bowel diseases. Carcinogenesis 2013; 34(4): 828-34.
115. Shibuya H, Iinuma H, Shimada R, Horiuchi A, Watanabe T. Clinicopathological and prognostic value of microRNA-21 and microRNA-155 in colorectal cancer. Oncology 2010; 79(3-4): 313- 20.
116. Onyeagucha BC, Mercado-Pimentel ME, Hutchison J, Flemington EK, Nelson MA. S100P/RAGE signaling regulates microRNA-155 expression via AP-1 activation in colon cancer. Exp Cell Res 2013; 319(13): 2081-90.
117. Valeri N, Gasparini P, Fabbri M, et al. Modulation of mismatch repair and genomic stability by miR-155. Proc Natl Acad Sci USA 2010; 107(15): 6982-7.
118. Tili E, Michaille JJ, Wernicke D, et al. Mutator activity induced by microRNA-155 (miR-155) links inflammation and cancer. Proc Natl Acad Sci USA 2011; 108(12): 4908-13.
119. Kutty RK, Nagineni CN, Samuel W, Vijayasarathy C, Hooks JJ, Redmond TM. Inflammatory cytokines regulate microRNA-155 expression in human retinal pigment epithelial cells by activating JAK/STAT pathway. Biochem Biophys Res Commun 2010; 402(2): 390-5.
120. Su C, Hou Z, Zhang C, Tian Z, Zhang J. Ectopic expression of microRNA-155 enhances innate antiviral immunity against HBV infection in human hepatoma cells. Virol J 2011; 8: 354.
121. Kutty RK, Nagineni CN, Samuel W, Vijayasarathy C, Hooks JJ, Redmond TM. Inflammatory cytokines regulate microRNA-155 expression in human retinal pigment epithelial cells by activating JAK/STAT pathway. Biochem Biophys Res Commun 2010; 402(2): 390-5.
122. Bakirtzi K, Hatziapostolou M, Karagiannides I, et al. Neurotensin signaling activates microRNAs-21 and -155 and Akt, promotes tumor growth in mice, and is increased in human colon tumors. Gastroenterology 2011; 141(5): 1749-61.
123. Borchert GM, Holton NW, Larson ED. Repression of human activation induced cytidine deaminase by miR-93 and miR-155. BMC Cancer 2011; 11: 347.
124. Matsumoto Y, Marusawa H, Kinoshita K, et al. Helicobacter pylori infection triggers aberrant expression of activation-induced cytidine deaminase in gastric epithelium. Nat Med 2007; 13(4): 470-6.
125. Endo Y, Marusawa H, Kinoshita K, et al. Expression of activationinduced cytidine deaminase in human hepatocytes via NF-kappaB signaling. Oncogene 2007; 26(38): 5587-95.
126. Mechtcheriakova D, Svoboda M, Meshcheryakova A, Jensen- Jarolim E. Activation-induced cytidine deaminase (AID) linking immunity, chronic inflammation, and cancer. Cancer Immunol Immunother 2012; 61(9): 1591-8.
127. Cervigne NK, Reis PP, Machado J, et al. Identification of a microRNA signature associated with progression of leukoplakia to oral carcinoma. Hum Mol Genet 2009; 18(24): 4818-29.
128. Jiang J, Zheng X, Xu X, et al. Prognostic significance of miR-181b and miR-21 in gastric cancer patients treated with S-1/Oxaliplatin or Doxifluridine/Oxaliplatin. PLoS One 2011; 6(8): e23271.
129. Nakajima G, Hayashi K, Xi Y, et al. Non-coding MicroRNAs hsalet- 7g and hsa-miR-181b are associated with chemoresponse to s-1 in colon cancer. Cancer Genom Proteomics 2006; 3(5): 317-24.